EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Update on the Role of Rifaximin in Digestive Diseases

Dan Lucian Dumitrascu, Igor Bakulin, Annalisa Berzigotti, Marília Cravo, Laura Gombošová, Milan Lukas, Anna Pietrzak, José María Remes-Troche, Manuel Romero-Gómez, Mercedes Amieva Balmori, Tiago Cúrdia Gonçalves, Lamine Hamzaoui und 9 weitere

Journal of Gastrointestinal and Liver Diseases · 01.04.2023 · 32 (1) · 92-109

DOI: 10.15403/jgld-4871 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Gastrointestinal and Liver Diseases, online erschienen am 01.04.2023. Verfasst von Dan Lucian Dumitrascu und 20 weiteren Autor:innen. Beteiligte Einrichtung: Iuliu Hatieganu University of Medicine and Pharmacy, Cluj County Clinical Emergency Hospital, Cluj-Napoca, Romania. ddumitrascu@umfcluj.ro. Hauptthemen laut MEDLINE: Irritable Bowel Syndrome, Rifamycins, Hepatic Encephalopathy, Diverticular Diseases. Die Arbeit wurde bisher 14-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Various environmental factors affecting the human microbiota may lead to gut microbial imbalance and to the development of pathologies. Alterations of gut microbiota have been firmly implicated in digestive diseases such as hepatic encephalopathy, irritable bowel syndrome and diverticular disease. However, while these three conditions may all be related to dysfunction of the gut-liver-brain axis, the precise pathophysiology appears to differ somewhat for each. Herein, current knowledge on the pathophysiology of hepatic encephalopathy, irritable bowel syndrome, and diverticular disease are reviewed, with a special focus on the gut microbiota modulation associated with these disorders during therapy with rifaximin. In general, the evidence for the efficacy of rifaximin in hepatic encephalopathy appears to be well consolidated, although it is less supported for irritable bowel syndrome and diverticular disease. We reviewed current clinical practice for the management of these clinical conditions and underlined the desirability of more real-world studies to fully understand the potential of rifaximin in these clinical situations and obtain even more precise indications for the use of the drug.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Irritable Bowel SyndromeRifamycinsHepatic EncephalopathyDiverticular DiseasesHumansRifaximin

Substanzen

RifaximinRifamycins

Autor:innen und Institutionen

  • Iuliu Hatieganu University of Medicine and Pharmacy, Cluj County Clinical Emergency Hospital, Cluj-Napoca, Romania. ddumitrascu@umfcluj.ro.
  • Mechnikov North-Western State Medical University, Saint Petersburg, Russia. email@notprovided.com.
  • Department of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, Bern, Switzerland. email@notprovided.com.
  • Serviço de gastrenterologia hospital da luz Lisboa and faculdade de medicina da universidade de Lisboa. Lisbon, Portugal. email@notprovided.com.
  • II Internal Clinic, University Hospital of L. Pasteur and Medical faculty of P.J.Šafarik University, Košice, Slovakia. email@notprovided.com.
  • Clinical and Research Centre for Inflammatory Bowel Diseases, ISCARE IVF Clinical Center Českomoravská, Prague, Czech Republic. email@notprovided.com.

Zitieren

APA

Dumitrascu, D. L., Bakulin, I., Berzigotti, A., Cravo, M., Gombošová, L., Lukas, M., Pietrzak, A., Remes-Troche, J. M., Romero-Gómez, M., Balmori, M. A., Gonçalves, T. C., Hamzaoui, L., Juricek, R., Moreira, L., Neubauer, K., Surdea-Blaga, T., Tikhonov, I. N., Trna, J., Ianiro, G., …, & Gasbarrini, A. (2023). Update on the Role of Rifaximin in Digestive Diseases. Journal of Gastrointestinal and Liver Diseases, 32(1), 92-109. https://doi.org/10.15403/jgld-4871

Vancouver

Dumitrascu DL, Bakulin I, Berzigotti A, Cravo M, Gombošová L, Lukas M, et al. Update on the Role of Rifaximin in Digestive Diseases. Journal of Gastrointestinal and Liver Diseases. 2023;32(1):92-109. doi:10.15403/jgld-4871

BibTeX
@article{Dumitrascu2023,
  author = {Dumitrascu, Dan Lucian and Bakulin, Igor and Berzigotti, Annalisa and Cravo, Marília and Gombošová, Laura and Lukas, Milan and Pietrzak, Anna and Remes-Troche, José María and Romero-Gómez, Manuel and Balmori, Mercedes Amieva and Gonçalves, Tiago Cúrdia and Hamzaoui, Lamine and Juricek, Radovan and Moreira, Leticia and Neubauer, Katarzyna and Surdea-Blaga, Teodora and Tikhonov, Igor N and Trna, Jan and Ianiro, Gianluca and Ponziani, Francesca Romana and Gasbarrini, Antonio},
  title = {Update on the Role of Rifaximin in Digestive Diseases},
  journal = {Journal of Gastrointestinal and Liver Diseases},
  year = {2023},
  volume = {32},
  number = {1},
  pages = {92--109},
  doi = {10.15403/jgld-4871}
}
Kostenlos starten →